Drug Approval | January 17, 2022
Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson injection
The company has 47 ANDA's pending approval with the U.S.FDA
The company has 47 ANDA's pending approval with the U.S.FDA
The company reports revenue growth of 26% and PAT growth of 21% YoY
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
This program, titled "Food Supplementation and Capacity Building Support for Improved Nutrition in Malinao, Aklan," aligns with the country’s national health
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the US by Glenmark Therapeutics, USA.
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
403 entries from 22 states covering 168 districts highlight groundbreaking initiatives vital to improving national nutrition metrics.
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Subscribe To Our Newsletter & Stay Updated
